This week, updates related to "certificates" were released for Java, Node.js, Go, and Python respectively. While they may ...

The country’s pharmaceutical industry has grown big enough to shift from low-cost generics to developing new drugs, said three of the country’s major pharma companies, pointing to China’s rapid shift ...

Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home. Credit...Video by Harsha Vadlamani Supported by By Alex Travelli ...

Illinois residents who purchased a generic drug between May 2009 and December 2019 could be eligible for payouts as part of a series of allegations that drug companies conspired to manipulate prices.

Did you pay for a generic prescription drug between May 2009 and December 2019? If so, you may be eligible to receive money from settlements involving some generic drug manufacturers. The Pennsylvania ...

If you take a patented, brand-name medication — a cancer biologic, an autoimmune drug, a specialty injection — the supply chain behind that drug is about to be permanently restructured, starting at 12 ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The most common prescription drugs you pick up at the pharmacy counter or fill via mail order will likely get more expensive under President Donald Trump's plan to assess a 100% tariff on imported ...

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for ...

President Donald Trump announced Tuesday that imported generic drugs will remain tariff-free for the next two years before facing steep new import duties, saying the move is designed to encourage ...

President Donald Trump on Tuesday announced a plan to impose a 100 percent tariff on generic drugs starting in August 2028 as part of a bid to push pharmaceutical production back to the United States.

A multiyear “tariff cliff” sets 0% through July 2028, then 100% for one year and 200% thereafter, explicitly tying penalties to failure to establish US manufacturing capacity. Sparse implementation ...